You have 9 free searches left this month | for more free features.

Condition

Melanoma (2)

BRAF V600 Colorectal Cancer (1)

Myelofibrosis (1)

Non-Small Cell Lung Cancer (1)

Non-Small-Cell Lung Carcinoma (1)

Other Solid Tumors (1)

Ovarian Neoplasms (1)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Suspended (1)

Terminated (1)

Sign in for free

Phase

phase 1 (3)

phase 1/phase 2 (1)

Sponsor

Novartis Pharmaceuticals (4)

Collaborator

Study Documents

Intervention Type

drug (4)

biological (1)

Funder Type

Industry (4)

Study Type

Interventional (4)

ltt462

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

NSCLC, Melanoma Trial in Worldwide (LXH254, LTT462, Trametinib)

Active, not recruiting

Non-Small Cell Lung Cancer
Melanoma

LXH254
+3 more

San Diego, California
+31 more

Sep 12, 2022

BRAF V600 Colorectal Cancer Trial in Worldwide (Dabrafenib, LTT462, Trametinib)

Recruiting

BRAF V600 Colorectal Cancer

Dabrafenib
+6 more

Los Angeles, California
+17 more

Jun 7, 2022

Myelofibrosis Trial in Worldwide (Ruxolitinib, Siremadlin, Crizanlizumab)

Suspended

Myelofibrosis

Ruxolitinib
+5 more

Adelaide, South Australia, Australia
+37 more

Aug 18, 2022

Ovarian Tumors, Non-Small-Cell Lung Carcinoma, Melanoma Trial in Worldwide (LTT462)

Terminated

Has Results

Ovarian Neoplasms
+3 more

LTT462

New York, New York
+6 more

Aug 15, 2019